La Jolla Pharmaceutical Company (LJPC)
Company Description
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases.
The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older.
It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia.
The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA.
La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.
| Country | United States |
| Founded | 1989 |
| IPO Date | Jun 3, 1994 |
| Industry | Biotechnology |
| Sector | Health Care |
| Employees | 61 |
Contact Details
Address:
4550 Towne Centre Ct San Diego, California 92121-1900 United States | |
| Phone | 617 715 3600 |
| Website | lajollapharmaceutical.com |
Stock Details
| Ticker Symbol | LJPC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| CIK Code | 0000920465 |
| CUSIP Number | 503459505 |
| ISIN Number | US5034596040 |
| Employer ID | 33-0361285 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Larry G. Edwards | President, Chief Executive Officer and Director |
| Michael S. Hearne | Chief Financial Officer and Secretary |
| Paula Rusu | Vice President of Operations |
| Sandra Vedrick | Senior Director of Investor Relations and Human Resources |
| Luke Seikkula | Senior Vice President of Pharmaceutical Operations |
| Dr. Lakhmir S. Chawla M.D. | Consultant |
| Stewart M. Kroll | Chief Development Officer |
| Mark D. Williams | Senior Vice President of Medical Affairs |
| Tony N. Hodges FACP, M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 17, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 2, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| May 17, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| May 16, 2022 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
| May 3, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| May 2, 2022 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] |
| Apr 18, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Apr 18, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Apr 4, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Apr 4, 2022 | 4 | Statement of changes in beneficial ownership of securities |